Daniel R. Hoffman, Ph.D.

Daniel R. Hoffman, Ph.D.

President, Pharmaceutical Business Research Associates

Latest Stories
Opinion

As the COVID-19 pandemic raged, pharmaceutical firms quietly raised drug prices | Expert Opinion

Amid all this suffering from COVID-19, the pharma companies last month raised drug prices by an average that’s more than three time the cost of living increase.

Pharma distorts the facts to keep Medicare from negotiating drug prices

The AMA's central argument against this valuable piece of legislation was its contention that government-supported health care would pave the way to the horror of socialized medicine.